Janux Therapeutics, Inc. (NASDAQ: JANX) is a Healthcare company (Biotechnology) with a market capitalization of $655M. The Maz Rating grades it against the other companies in its sector.
Janux Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.71, Janux Therapeutics, Inc. trades at 28.1x sales and 0.7x book value. Over the last twelve months it generated about $23M of revenue and a net loss of $98M. It runs an operating margin of -599.3% and a net margin of -428.7%. It shows return on equity of -10.7%, return on invested capital of -15.0% and a free cash flow yield of -8.3%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 17.69. Over the past 52 weeks the share price ranged from $10.50 to $35.34, with a beta of 2.39.
Janux Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 12 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.